Leveraging the Therapeutic Potential of Mitochondria
Ischemia-reperfusion injury is the world’s number one killer. It arises when the blood flow to a part of the body is interrupted (ischemia) and subsequently re- introduced (reperfusion). It manifests itself e.g. in heart attacks, strokes, or organ transplantation . There are more than 3 million cases in the US and Europe every year.
Past attempts to treat ischemia-reperfusion injury failed. Their key shortcoming was the inability to address mitochondria dysfunction induced during ischemia. As the mitochondria, the powerhouses of the cell, fail, cell functions deteriorate, leading to cell death.
cellvie’s approach is radically different in that it reinvigorates that failing energy metabolism. Viable mitochondria are transplanted, replacing and augmenting damaged mitochondria. It is like jump- starting a car, allowing the cells to reestablish the energy supply.
As the first indication, the Harvard-spinoff picked organ transplantation, where cellvie expects to increase organ donor availability by up to 30%. Safety and efficacy was established in more than 20 pre-clinical studies and an ongoing clinical pilot at Boston Children’s Hospital. Subsequently, cellvie will pursue heart attacks, with ~1.3M cases in the US and EU.
Cellvie was founded in the US in 2018 by Drs James McCully, Alexander Schueller, Pedro del Nido and Sitaram Emani and is headquartered close to Zürich, Switzerland.